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Feline chronic gingivostomatitis (FCGS) is a disease characterized by protracted 
and potentially debilitating oral inflammation in cats, the etiology of which is currently 
unknown. The purpose of this review is to apply an evidence-based medicine approach 
to systematically review and critically evaluate the scientific literature reporting the out-
come of medical and surgical management of FCGS. Those articles meeting inclusion 
criteria were reviewed and assigned an “Experimental Design Grade” (EDG) and an 
“Evidence Grade” (EG) in order to score relative strength of study design and produced 
data. Studies were evaluated and compared, especially highlighting the treatments, the 
outcomes, and the therapeutic success rates. This review found a lack of consistency 
between articles’ data, rendering direct comparison of results unreliable. The field of 
FCGS research, and ultimately patient care, would benefit from standardizing studies by 
adopting use of a consistent semi-quantitative scoring system and extending follow-up 
duration. Future researchers should commit to large prospective studies that compare 
existing treatments and demonstrate the promise of new treatments.
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iNTRODUCTiON
Feline chronic gingivostomatitis (FCGS) is a painful, often debilitating, condition in cats charac-
terized by protracted oral inflammation typically lasting months to years. More specifically, it is 
differentiated from gingivitis when the inflammation crosses the mucogingival junction and extends 
to the buccal and caudal oral mucosa; classically, there are erosive and/or proliferative inflammatory 
mucosal lesions lateral to the palatoglossal folds (1, 2). The reported prevalence of FCGS ranges from 
0.7 to 12.0% (3–6). Given that there are ~74–96 million cats owned in the United States (7), this 
translates to an estimated disease burden of at least 500,000 and upwards of 11 million cats.
Histologically, lesions are primarily infiltrated by lymphocytes and plasma cells, with fewer 
neutrophils, macrophage-like cells, and mast cells (8, 9). In addition, it has recently been noted that 
CD3+ T cells are present within the epithelium and submucosa of oral mucosa effaced by FCGS, 
whereas CD20+ B cells are mainly present within the subepithelial stroma (10). Histology is useful 
to confirm the diagnosis, and is necessary for academic and research purposes. However, clinical 
appearance and clinical signs may be sufficient for diagnosis. Affected cats may suffer from moder-
ate to severe oral pain, halitosis, ptyalism, decreased grooming, hyporexia, weight loss, irritability, 
TAbLe 2 | Grading scheme used to score the quality of data for 
manuscripts included in this systematic review, modified from a 
previously devised scoring system (34).
evidence gradea (eG) For FCGS treatment outcome being measured
A Histology
B Semi-quantitative scoring system of lesion gross 
appearance and/or owner-reported clinical signs
C Subjective outcome measures of lesion gross 
appearance and/or owner-reported clinical signs 
without a defined semi-quantitative scoring system
aIf a combination of outcome types were reported, the higher evidence grade was 
assigned (A > B > C).
TAbLe 1 | Grading scheme used to score the quality of experimental 
design for manuscripts included in this systematic review, modified from 
a grading system published by the Oxford Centre for evidence-based 
Medicine (30).
experimental design 
grade (eDG)
Categories of therapeutic FCGS studies
I Randomized, controlled, double-blinded prospective 
clinical trials
II Prospective clinical trials (± control group)
III Retrospective case series, n > 10; case–control study
IV Retrospective case series, n < 10
V Single patient case report; expert opinion
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withdrawn behavior, and/or decreased activity (11, 12). Quality 
of life can be so severely affected that owners elect for humane 
euthanasia (3, 10, 13).
The etiology of FCGS remains elusive, but it is generally 
accepted that FCGS arises from an inappropriate immune 
response to oral antigenic stimulation, potentially multifactorial 
in nature and possibly with varying inciting causes (12, 14, 15). 
Myriad maladies have been implicated, from systemic pathogens 
(feline calicivirus, herpesvirus, leukemia virus, immunodefi-
ciency virus, and Bartonella), to dental disease (feline resorptive 
lesions, periodontal disease), to hypersensitivity (overreaction to 
plaque bacteria, food allergies) (12, 14, 16–27). Detection of cir-
culating T cells in cats suffering from FCGS supports the theory 
that the disease arises from an aberrant response to chronic, oral, 
antigenic stimulation stemming from clinical or subclinical viral 
infections (10, 14, 18, 27, 28).
Just as the underlying cause of FCGS is yet to be determined, 
a satisfactorily consistent and successful treatment regime is yet 
to be discovered. Many therapies have been pursued the past few 
decades, generally categorized as either medical or surgical man-
agement. The mainstay of medical therapy has traditionally been 
immunosuppression [i.e., corticosteroids (28) or cyclosporine 
(12)], while surgical treatment involves the extraction of premolar 
and molar teeth or the full dentition. These treatments are far 
from benign, with possible adverse effects ranging from polyuria, 
polydipsia, secondary diabetes mellitus, skin fragility, diminishing 
effectiveness over time (medical management), to postoperative 
pain and reduced function, owner psychological distress, and 
financial expense (surgical management). In order to discover an 
efficacious therapy with minimal side effects and in order to test 
the effectiveness of dental extractions, multiple studies have been 
conducted assessing the outcome of various therapies.
It may be postulated that current treatment options have 
remained unrewarding, with variable response rates, because 
of the multifactorial nature of FCGS, or because the inciting 
cause may differ between patients. Until the exact etiology is 
discovered, and therapy can, thus, be targeted accordingly, it is 
important to critically evaluate current treatment alternatives by 
utilizing an evidence-based medicine approach. Evidence-based 
medicine encourages clinicians to make decisions powered by the 
best available evidence gained from the scientific method (29). In 
compiling and appraising the current literature on FCGS treat-
ments, the benefits and limitations of therapies can be weighed, 
while ultimately highlighting the need for further high-quality 
research on this topic. The aim of this study was to apply an 
evidence-based medicine approach to systemically review and 
critically evaluate the scientific literature reporting the outcome 
of medical and surgical treatments for FCGS.
MATeRiALS AND MeTHODS
A systematic literature search was performed, including articles 
available through February 6, 2016, for manuscripts relating to 
the treatment of FCGS. The on-line databases PubMed, Web of 
Science, and CAB Abstracts were searched using the following 
terms: [(cat OR cats OR feline OR felines) AND (stomatitis OR 
gingivostomatitis) AND (treatment)].
Inclusion and exclusion criteria for article selection were 
predetermined to reduce bias. Articles included in this study are 
those published in peer-reviewed journals that discuss spontane-
ously occurring FCGS and original data about its treatment in 
domestic cats. A clearly defined treatment protocol for each cat 
must be provided (i.e., consistent dose of medication given to 
each treatment cat). Articles were excluded if not written in the 
English language, if FCGS is presented as a sequela of another 
disease for which treatment is primarily aimed (such as feline 
leukemia virus or feline immunodeficiency virus), if treatment 
of FCGS from a different study is summarized or recapitulated 
without contribution of new experimental or at least anecdotal 
data, or if a follow-up period is not delineated.
The authors read the titles, abstracts, and/or full text of the 
publications yielded in the database searches to determine 
study eligibility. Those articles meeting inclusion criteria were 
reviewed and were awarded an “Experimental Design Grade” 
(EDG), a scoring system of strongest (I) to weakest (V) evi-
dence modified from a grading system published by the Oxford 
Centre for Evidence-Based Medicine (Table 1) (30–33). Articles 
were also assigned an “Evidence Grade” (EG) of strongest (A) 
to weakest (C) evidence based on the type of outcome being 
measured, modified from a previously devised scoring system 
assessing quality of data (Table 2) (34). In reporting the success 
rate of the therapeutic intervention being tested, use of the 
term “cure” can be misleading given that the etiology of FCGS 
remains elusive; the phrases “resolution” of FCGS lesions and/
or clinical signs or “clinical remission” are more appropriate and 
will, thus, be utilized in this review when describing clinical 
outcome.
TAbLe 3 | Summary of the data collected from the manuscripts included in this systematic review.
Reference Publication  
year
nta ncb Treatment tested; 
control administered, 
if applicable
Outcome being 
measured
Duration of 
follow-up 
(months)
% ntc; % ncd eDG eG Funding source
Kavanagh (43) 1998 1 0 Zincreo germicidal 
astringent obtundent 
(topically)
Clinical signs as reported 
per owner
0.5 100; n/a V C None stated
Mayr et al. (38) 1991 33 39 Local paramunization with 
PIND-ORF (parapoxvirus 
ovis); “conventional 
treatment”
Not explicitly discussed 
(implied gross appearance 
of oral lesions)
6–18 42; 13 II C None stated
Hennet (39) 1997 30 0 Dental extractions: 24 cats 
had all premolar and molar 
teeth extracted, 2 had full-
mouth extractions, 4 had 
one to five premolar teeth 
remaining
Semi-quantitative scoring 
system combining gross 
appearance of oral 
lesions, need for ongoing 
medical management, 
owner-reported clinical 
signs
11–24 80 (60); n/a III B None stated
Addie et al. (44) 2003 1 0 Thalidomide + Lactoferrin 
powder (topically)
Calicivirus shedding; gross 
appearance of oral lesions
22 100; n/a V C Morinaga Foods; 
Companion Animal 
Diagnostics, 
University of 
Glasgow
Baird (45) 2005 1 0 Extraction of all premolar 
and molar teeth
Gross appearance of oral 
lesions
2.2 100; n/a V C None stated
Vercelli et al. 
(40)
2006 8 0 Cyclosporine Semi-quantitative 
scoring system of gross 
appearance of oral lesions
3 100 (50); n/a III B None stated
Southerden 
and Gorrel (46)
2006 1 0 Recombinant feline 
interferon omega
Gross appearance of oral 
lesions
6 100; n/a V C None stated
Lewis et al. (47) 2007 1 0 Carbon dioxide laser Gross appearance of oral 
lesions
36 100; n/a V C None stated
Bellei et al. (11) 2008 21 0 Extraction of all premolar 
and molar teeth
Semi-quantitative 
scoring system of gross 
appearance of oral lesions
0.75 80.9 (57.1); n/a II B None stated
Hennet et al. 
(28)
2011 19 11 Recombinant feline 
interferon omega (topically); 
tapering course of 
prednisolone
Semi-quantitative 
scoring system of gross 
appearance of oral lesions 
and a variety of other 
clinical signs
3 45 (10); 23 (7.7) I B Virbac SAS, France
Corbee et al. 
(36)
2012 7 7 Diet with 10:1 ratio of 
omega-6 polyunsaturated 
fatty acid (PUFA) to 
omega-3 PUFA after 
premolar and molar teeth 
extractions; diet with 40:1 
ratio of omega-6 PUFA to 
omega-3 PUFA
Semi-quantitative 
scoring system of gross 
appearance of oral lesions
1 Not explicitly 
stated by 
authors – Jenna 
N. Winer’s 
interpretation: 
57; 85
I B None stated
Leal et al. (42) 2013 2 0 Recombinant feline 
interferon omega
Gross appearance of oral 
lesions and owner report 
of clinical signs
5–6 100; n/a IV C None stated
(Continued)
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The following data were extracted from each article included 
in this study: the name of the first (or only) author, publication 
year, the number of cats receiving treatment, the number of cats 
serving as controls, treatment(s) being tested, the control treat-
ment or placebo (if applicable), the outcome being measured, 
duration of follow-up, the percentage of cats receiving treatment 
that significantly improved or went into clinical remission per the 
authors, the percentage of cats receiving the control medication 
or placebo that significantly improved or went into clinical remis-
sion per the authors, and the study’s funding source (Table 3). 
Table 3 was arranged by publication year, so that trends over time 
could be appreciated.
Reference Publication  
year
nta ncb Treatment tested; 
control administered, 
if applicable
Outcome being 
measured
Duration of 
follow-up 
(months)
% ntc; % ncd eDG eG Funding source
Lommer (12) 2013 9 7 Cyclosporine; cod liver 
oil with tuna flavoring 
(placebo)
Semi-quantitative 
scoring system of gross 
appearance of oral 
lesions and a variety of 
other clinical signs
1.5 77.8 (45.5); 
14.3
I B Academy of 
Veterinary Dentistry
Hung et al. (37) 2014 5e 5 Bovine lactoferrin oral 
spray + piroxicam; 
piroxicam
Histology; semi-
quantitative scoring 
system of gross 
appearance of oral 
lesions, clinical signs, and 
quality of life
3 77; not 
explicitly 
stated
I A Happy Harvest 
Corporation
Jennings et al. 
(41)
2015 95 0 Dental extractions: 
full mouth or 
premolar + molar 
extractions
Semi-quantitative 
scoring system 
combining gross 
appearance of oral 
lesions, need for 
ongoing medical 
management, owner-
reported clinical signs
1–88.5 
(mean 7.7)
67.4 (28.4); 
n/a
III B None stated
Arzi et al. (10) 2016 7 0 Fresh, autologous, 
adipose-derived 
mesenchymal stem cell 
IV injections
Histology (n = 3); semi-
quantitative scoring 
system combining gross 
appearance of oral 
lesions and owner-
reported clinical signs
6–24 71.4 (42.8); 
n/a
II A NIH, WINN Feline 
Foundation, 
San Francisco 
Foundation
ant, number of cats with FCGS to which trial treatment medication was administered (does not include cats that dropped out of study).
bnc, number of cats with FCGS to which control medication/placebo was administered (does not include cats that dropped out of study).
c% nt, percentage of nt that went into clinical remission and/or significantly improved per authors; number in parentheses represents the percentage of nt patients that went into 
clinical remission per authors (excludes cats that significantly improved but did not achieve remission).
d% nc, percentage of nc that went into clinical remission and/or significantly improved per authors; number in parentheses represents the percentage of nc patients that went into 
clinical remission per authors (excludes cats that significantly improved but did not achieve remission).
eAfter 4 weeks, control cats were converted to treatment cats; so for weeks 5–12 of this study, there were 10 cats receiving bovine lactoferrin oral spray + piroxicam PO.
TAbLe 3 | Continued
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ReSULTS
Database searches yielded 521 articles for initial review; ulti-
mately 16 met the inclusion criteria. A flowchart (Figure  1) 
modified from the “Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses” (PRISMA) (35) guidelines is 
provided to outline the process by which the search results were 
narrowed to the 16 articles included in this systematic review. 
The most common reasons for study exclusion were manuscripts 
focusing on species other than cats (i.e., humans) as well as 
articles discussing treatment of other feline diseases, such as 
feline immunodeficiency virus, and mentioning stomatitis as a 
clinical sign or sequela. After assessing the included 16 studies, 
4 were assigned an EDG of I (12, 28, 36, 37), 3 were assigned an 
EDG of II (10, 11, 38), 3 were assigned an EDG of III (39–41), 
1 was assigned an EDG of IV (42), and 5 were assigned an EDG 
of V (43–47). Seven studies (43.8%) were prospective clinical 
trials, three studies were retrospective (18.7%), and six studies 
were case reports presenting the outcome of one or two cats 
(37.5%). There were 10 forms of medical management evaluated 
in these studies: Zincreo germicidal astringent obtundent (43), 
local paramunization with PIND-ORF (parapoxvirus ovis) (38), 
thalidomide (44), lactoferrin (37, 44), cyclosporine (12, 40), 
recombinant feline interferon omega (28, 42, 46), prednisolone 
(28), diet (36), piroxicam (37), and autologous mesenchymal 
stem cells (10). There were six studies that focused on surgi-
cal management, discussing efficacy of dental extractions (11, 
36, 39, 41, 45) and use of carbon dioxide laser treatment as an 
adjunct to dental extractions (47). The reported mechanism of 
action of these treatments is as follows: local paramunization 
(38), thalidomide (44), lactoferrin (37, 44), cyclosporine (12, 
40), recombinant feline interferon omega (28, 42, 46), and autol-
ogous mesenchymal stem cells (10) elicit immunomodulatory 
effects; prednisolone (28) and piroxicam (37) reduce inflamma-
tion; lactoferrin (37, 44) inhibits bacterial growth; recombinant 
feline interferon omega (28, 42, 46) impedes viral replication; 
diet (36) accelerates healing and reduces inflammation; carbon 
dioxide laser (47) removes proliferative tissue and stimulates 
fibrosis; and dental extractions reduce immune stimulation via 
eliminating plaque (11, 36, 39, 41, 45). The mechanism of action 
of Zincreo germicidal astringent obtundent was not directly 
reported (43).
The most common outcome measurement was utilization 
of semi-quantitative scoring systems ranking gross appear-
ance of oral lesions and/or owner-reported clinical signs and/
or the need for ongoing medical management (n = 7, 43.8%) 
Articles identified through 
database searching
(n =  521)
Sc
re
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g
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cl
ud
ed
E
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ty
Id
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ic
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n
Articles after duplicates were removed, 
published in English
(n =  320)
Articles assessed for 
eligibility 
(n = 60)
Articles excluded because did not meet 
inclusion criteria 
(n = 44)
Articles included in 
systematic review
(n = 16)
Articles excluded because pertain to 
humans/species other than cats
(n = 198)
Articles excluded because pertain to 
cat diseases other than FCGS 
(n = 62)
FiGURe 1 | Flowchart modified from the “Preferred Reporting items for Systematic Reviews and Meta-Analysis (PRiSMA) (35) guidelines,” 
demonstrating the process by which the search results were narrowed to the 16 articles included in this systematic review.
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(11,  12, 28, 36, 39–41), followed by reporting the qualitative 
gross appearance of oral lesions (n = 4, 25%) (42, 45–47). There 
were two studies (12.5%) that included both a semi-quantitative 
scoring system as well as mucosal histology post-treatment as 
their outcome measurements (10, 37), while another study 
measured shedding of calicivirus in addition to reporting 
the gross appearance of oral lesions (44). One study relied on 
clinical signs as reported by the owner over the phone (43). 
One study did not explicitly discuss the outcome measurement, 
which was inferred to be gross appearance of oral lesions (38). 
Thus, two studies produced level A evidence (10, 37), seven 
studies produced level B evidence (11, 12, 28, 36, 39–41), and 
seven studies produced level C evidence (38, 42–47).
Surgical Management
There were six articles that focused on surgical management of 
FCGS (11, 36, 39, 41, 45, 47). Of these, two articles were graded 
as level V C case reports discussing single cats; one cat under-
went premolar and molar tooth extractions and achieved clinical 
remission that was sustained for at least 2.2 months (45), while 
the other cat was treated adjunctively with a carbon dioxide laser 
after dental extractions and achieved clinical remission that was 
sustained for at least 36 months (47).
There were three articles specifically investigating the efficacy 
of dental extractions in groups of cats, each reporting grade 
B evidence (11, 39, 41). The earliest of the three articles (39) 
included a sample size of 30 cats, in which a 60% clinical remis-
sion rate was achieved (no visible lesions, no oral clinical signs), 
with an additional 20% of cats considered significantly improved 
without the need for ongoing therapy, 13.3% of cats showing little 
improvement, and 6.7% of cats making no improvement. The next 
article (11) assessed the results of dental extractions performed 
on 21 cats; of these, 57.1% achieved clinical remission, 23.8% 
improved, and 19.1% suffered relapses. The results of these two 
articles are strikingly similar, with ~80% of both groups demon-
strating substantial improvement or resolution of FCGS lesions 
and the remaining 20.0% of cats benefiting minimally or not at 
all from surgical treatment. The most recent and comprehensive 
article assessing dental extractions was a retrospective case series, 
including 95 cats treated with either full-mouth extractions or 
premolar and molar tooth extractions (41). This study reports that 
significantly fewer cats (28.4%, P = 0.002) recovered completely 
compared to the previous two studies (11, 39). While a greater 
percentage (39.0%) of cats showed substantial improvement, 
the authors point out that this was not statistically significantly 
different from the first extraction article’s (39) finding of 20.0% 
(P  =  0.077). At the last recheck examination, 26.3% of their 
patients showed little improvement and required ongoing medi-
cal management [again, not statically significantly different from 
the first extraction article’s (39) finding, P = 0.214]. In this study, 
6.3% of cats remained refractory to extraction treatment [yet 
again, not statically significantly different from the first extrac-
tion article’s (39) finding, P-value not provided]. Approximately 
one-third of the 95 cats had been treated with premolar and 
molar tooth extractions while the remaining approximately 
two-thirds were treated with full-mouth extractions; there was 
no significant difference in response to treatment between these 
groups (P = 0.377). These authors also found that treatment with 
6Winer et al. Literature Review of Gingivostomatitis Treatment
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antimicrobials, anti-inflammatories, or analgesics prior to or at 
the time of extractions was not associated with a better outcome. 
Cats that were reported to have resolution of abnormal behaviors 
associated with FCGS at the time of their first postoperative 
recheck had odds of a positive outcome (clinical remission or 
substantial improvement) 7.2 times as great as in cats without 
resolution. Just over two-thirds of the cats that achieved clinical 
remission or substantially improved did require additional medi-
cal management for a finite period of time beyond the immedi-
ate postoperative period, whereas the first study (39) reported 
no need for medical management in the 80% of cats that went 
into clinical remission or significantly improved, and the second 
study (11) did not discuss if ongoing medical management was 
necessary.
In the sixth article discussing dental extractions (36), the 
primary focus was not on surgical management, but instead the 
intent was to investigate if diets with differing omega-3 to omega-6 
polyunsaturated fatty acid ratios would affect inflammation and 
wound healing when fed to cats postoperatively after premolar 
and molar tooth extractions. Cats’ FCGS was scored utilizing 
a five-point semi-quantitative scale examining the degree of 
inflammation preoperatively and 4 weeks postoperatively. While 
there was no statistically significant difference between groups fed 
different diets (P = 0.366), overall, there was significant improve-
ment in FCGS scores of both groups (P =  0.017, P =  0.042), 
presumably owing to the dental extractions. With their data 
pooled, the 14 cats’ FCGS scores improved on average by 52.1% 
(range 0–72.0%).
Medical Management
The remaining 10 articles explore the efficacy of various medical 
management therapies (10, 12, 28, 37, 38, 40, 42–44, 46).
There are two studies that test the efficacy of oral cyclosporine; 
in the first (40), cyclosporine was administered to a group of eight 
cats that were not previously treated for FCGS with dental extrac-
tions, while in the second (12), cyclosporine was administered to 
nine edentulous cats. In the former study, 50.0% of cats achieved 
clinical remission, while the remaining cats showed 40.0–70.0% 
improvement in their semi-quantitative lesion scores during 
the 6-month follow-up period. In the latter study, 45.5% of cats 
achieved clinical remission, while 77.8% of cats showed a >40.0% 
improvement in their semi-quantitative stomatitis scores over the 
6-week study period; by contrast, only 1 of 7 (14.3%) of cats in the 
placebo group showed a >40% score improvement.
A relatively similar success rate was achieved in a pilot study 
exploring the efficacy of fresh, autologous, adipose-derived 
mesenchymal stem cells intravenously injected into seven cats 
(10). Over the 6- to 24-month follow-up period, 42.8% of cats 
(n = 3) went into clinical remission, 28.6% (n = 2) demonstrated 
substantial improvement, and 28.6% (n =  2) did not respond. 
This article was awarded a level A EG because it not only utilized 
a semi-quantitative scoring system but also included histology 
from cats that achieved either clinical remission, substantial 
improvement, or that failed to respond. Histology results paral-
leled clinical gross examination of the lesions. While harvesting 
mesenchymal stem cells from the patient’s fat may preclude this 
treatment from easily being adopted widely at this juncture, the 
authors state that additional investigations using fresh, allogeneic 
cells are ongoing. Another unique aspect of this article is that the 
authors identified a potential biomarker to predict therapeutic 
outcome of stem cell treatment.
There were three articles, each testing a different therapy 
[Zincreo (43), thalidomide with lactoferrin (44), and recombi-
nant feline interferon omega (46)], that were graded V C and 
each yielded a 100% remission rate in their single cat patient. 
In another article (42), graded IV C, recombinant feline inter-
feron omega was administered to two cats, yielding a 100% 
remission rate.
The remaining three articles that discuss medical manage-
ment included a control group (28, 37, 38). In one study (38), the 
success of treating with local paramunization using PIND-ORF 
(parapoxvirus ovis) versus “conventional treatment” (the authors 
did not define the specific control therapy) was compared. There 
were 33 cats treated with paramunization, resulting in 42.0% of 
them achieving clinical remission or substantially improving, 
while only 13.0% of the 39 cats receiving “conventional treatment” 
achieved the same positive results. Another study (37) tested the 
efficacy of bovine lactoferrin administered with piroxicam versus 
piroxicam alone as a control; 77.0% of cats receiving both medica-
tions achieved clinical remission or substantially improved after 
12 weeks, whereas the authors did not state the success rate of the 
control group, as control cases were converted to treatment cases 
after the fourth week. Finally, a study (28) compared the effec-
tiveness of recombinant feline interferon omega in 19 cats versus 
the control treatment of prednisolone in 11 cats; 45.0% of the 
treatment cats substantially improved (10.0% of which achieved 
clinical remission), while 23.0% of control cats substantially 
improved (7.0% of which achieved clinical remission). However, 
these differences between treatment and control group were not 
statistically significant.
DiSCUSSiON
To the authors’ knowledge, this is the first systematic review of 
the literature analytically evaluating the outcome of studies on 
therapeutics for FCGS. It is prudent to critically and systemati-
cally evaluate this literature, especially when studies have thus 
far failed to identify a consistent clinical resolution for this 
condition.
Lack of Statistical Power
Of the 16 articles included in this review, 6 were small retrospective 
case series or single patient case reports (EDG IV or V). Lacking 
any statistical power, these articles provide weak evidence. That 
being said, it is heartening that, in general, more recent studies 
have a higher EDG and EG than earlier studies. Ideally, studies 
would build off of the results of one another, expanding promis-
ing level V experiments to a level II or I clinical trial. However, 
in compiling FCGS articles, this is rarely the case. Instead, the 
literature is at times circuitous, expending efforts in studies that 
stand to change the overall conversation minimally. For example, 
after a level III B article (39) was published discussing efficacy 
of dental extractions in 30 cats, 8  years later a level V C case 
report (45) was published discussing success of premolar and 
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molar tooth extractions in a single cat, which does not advance 
collective knowledge about FCGS treatment. Similarly, a level V 
C single patient case report (46) published on recombinant feline 
interferon omega was followed 7 years later by a level IV C case 
report (42) published testing the same drug in two cats with an 
almost identical follow-up time and result.
inconsistent Outcome Measurements
This review identified that 9 of the 16 articles assessed outcome 
of FCGS treatment via semi-quantitative scoring systems. 
A  novel  custom scoring system was developed and defined in 
four of these articles (28, 36, 39, 40), while two articles utilized 
the same scoring system (10, 12), and three articles each modeled 
their scoring system off of different previously utilized scoring 
systems (11, 37, 41). This represents a significant obstacle both to 
the comparison of existing results and for the planning of future 
studies. Recorded outcome measures in articles included in this 
study include gross examination of oral lesions by veterinarians, 
other physical exam findings (such as body weight or body 
condition score or prominence of mandibular lymph nodes), 
owner-reported clinical signs in the home setting, and/or owner-
perceived quality of life for their cat. This review not only found 
little consistency between articles in the scoring system used to 
record outcome but also in the duration of follow-up. Follow-up 
periods ranged from 2 (43) to 354 weeks (41). The lack of consist-
ency between studies in data reporting makes direct comparison 
of results problematic. In order to draw sound comparisons, 
ideally all studies would adopt the same validated outcome 
measure, with histology of oral lesions being the gold standard. 
Universal adoption of a standardized semi-quantitative scoring 
system validated with histopathology results would be ideal. A 
longer follow-up time is obviously superior to a shorter follow-up 
period, but at some point practicality limitations outweigh the 
desire to continue collecting data. No study has explored the time 
cutoff after which response to either medical or surgical therapy 
remains static; until such a study is performed, it is reasonable 
that prospective studies continue collecting data at least 6 months 
beyond plateaued response to treatment.
Refractory versus Naïve FCGS
In analyzing articles whose focus is medical management, it is 
important to bear in mind if the subjects are refractory to histori-
cally performed dental extractions, if they have failed to respond 
to previous medical management attempts, or if their FCGS is 
naïve to any previous therapeutic intervention. For example, it is 
noteworthy that the clinical remission rate was strikingly similar 
for cats involved in the two cyclosporine studies (12, 40) despite 
the fact that one group of cats had been resistant to previous 
medical management (40), whereas the other group had been 
refractory to full-mouth extractions (12).
experimental Design Grade and 
evidence Grade
The grading systems utilized in this study provide a framework for 
analyzing experiment design and strength of the data reported. 
The grading process is not intended to criticize specific articles, 
and it is important to bear in mind that each article has its own 
strengths and weaknesses. The key components that comprise a 
strong FCGS study include the following: a large enough study 
population to be representative, a prospective experimental 
design, a quantitative or at least semi-quantitative scoring system 
for disease severity, and a long enough duration of follow-up to 
convince the reader that results will be sustained indefinitely. 
None of the articles included in this review meets all four of the 
above criteria.
There were four articles awarded a level I EDG, in part because 
they included either a control group (28, 36, 37) or a placebo group 
(12). While it is generally accepted that studies are strengthened by 
the inclusion of a control or placebo group, this practice is poten-
tially problematic when applied to FCGS treatment clinical trials. 
One such problem is deciding upon the treatment administered 
to the control group. Each of the controlled studies included in 
this systematic review tests a different control treatment, namely 
a corticosteroid (28), a non-steroidal anti-inflammatory (37), or 
a diet (36). While selection of these control group treatments was 
intended to provide internal validation via direct comparison 
within studies, it renders comparison across studies difficult, if 
not meaningless. Control therapies have not been standardized; 
it could be informative to define a standardized control therapy 
against which to compare novel therapies. A second problem is 
the ethical dilemma that arises when cats enrolled in control or 
placebo groups experience prolonged suffering by not receiving 
superior, or any, treatment. One approach could, thus, be to 
eliminate placebo and control groups altogether. A benefit of this 
action is that more cats would be available to receive and test 
a treatment. Furthermore, spontaneous recovery or significant 
clinical improvement has never been reported in cats with refrac-
tory FCGS, which may devalue control or placebo groups (10). 
However, best practice in study design strives for the inclusion of 
control and placebo groups. The ethical predicament that accom-
panies use of control and placebo groups could be mitigated by 
allowing for analgesic administration to all cats throughout the 
study period. Additionally, if the treatment being tested is found 
to be promising, the cats in the control or placebo groups could 
be converted to cats receiving treatment, as occurred in the single 
placebo-controlled study discussed in this systematic review (i.e., 
a randomized controlled crossover study with one of the two 
treatments being a placebo) (12).
There were two articles awarded a level A EG for including 
histology of lesions post-treatment (10, 37). While FCGS is fre-
quently diagnosed on the basis of clinical appearance and clinical 
signs, it is still beneficial to perform histopathology, ideally before 
and after treatment. Histopathology is useful not only to confirm 
the diagnosis (i.e., differentiate it from other diseases, such as 
squamous cell carcinoma) but also to help further classify and 
understand the lesion. The current lack of knowledge regarding 
the etiology of FCGS and the extent of mucosal response to 
therapy can only definitively be assessed via histological and 
immunohistochemical means, which validate and compliment 
the subjective assessment of clinical appearance and clinical 
signs. The more histopathological knowledge we have of this 
disease, the more potential there is to discovering the underlying 
etiology(s) and the most efficacious treatments.
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Study Limitations
There are limitations that may potentially affect the results and 
conclusions produced by this study. Inclusion and exclusion cri-
teria were pre-defined to minimize bias; however, these criteria 
resulted in the exclusion of potentially influential articles. For 
example, an article exploring the efficacy of bovine lactoferrin 
was excluded because the study lacked a standardized defini-
tion of FCGS, with one experimental cat’s disease described 
as “severe gingivitis with hemorrhage” (48). Another article 
reporting the outcome of various therapies, including corticos-
teroids, antibiotics, megestrol acetate, levamisole, azathioprine, 
cyclophosphamide, and injectable gold (aurothioglucose) was 
excluded due to lack of defined treatment protocol, with incon-
sistent drug doses and no reporting of which cats received which 
treatment(s) (16). Another article examining various medical 
therapies, including diet adjustment, megestrol acetate, antibiot-
ics, corticosteroids, levamisole, and mouthwash, was excluded 
because of inconsistent treatment protocols as well as no defined 
follow-up timeframe (8).
A second potential limitation is that only treatments for 
which there have been peer-reviewed studies published in the 
English language could be included in this study. Although 
chlorambucil, vincristine, 5-fluorouracil, sulodexide, tacrolimus 
topical, colchicine, and lysine have all been suggested as pos-
sible therapies (23), to the authors’ knowledge, there are no 
published reports assessing their efficacy within the veterinary 
peer-reviewed literature.
Because of the heterogeneity in outcome measurements, study 
design, population sizes, and follow-up times, it was impossible to 
perform a meta-analysis of articles’ data, and, thus, results of each 
study have been reported individually.
Future Directions
In considering treatment options for FCGS, veterinarians should 
strive to adopt an evidence-based approach to their therapeutic 
recommendations. While studies have shown the percentage of 
cats that respond to various medical and surgical interventions, 
clinicians must sift through these data and apply it to their 
individual patients. Many questions still remain – for which cats 
should medical management be attempted initially versus recom-
mending surgical management at the time of initial diagnosis? 
At what point should medical management be discontinued in 
favor of switching to surgical management if a cat is failing to 
respond to therapy, versus administering an alternate medical 
management? Can we predict which cats will respond to various 
treatment types?
Veterinarians should strive to improve the quality of FCGS 
research and, thus, the evidence base available to inform col-
leagues’ therapeutic recommendations in order to optimize patient 
care. In addition, we should bear in mind both the strengths and 
weaknesses of the current literature when drawing conclusions. 
Large prospective studies are needed to compare existing treat-
ments and demonstrate the promise of new treatments. With the 
emergence of novel and innovative therapeutics, the field of FCGS 
research would benefit from standardizing studies by adopting 
use of the same quantitative or semi-quantitative scoring system 
and extending follow-up duration to at least 6 months beyond 
plateaued response to treatment.
CONCLUSiON
The current peer-reviewed literature on FCGS therapeutic 
outcome has demonstrated the statistical success rates of various 
treatments, reporting the percentage of cats achieving clinical 
remission when treated with either medical or surgical manage-
ment. Future studies recapitulating this same point of view may 
further refine the success rates of therapies already in use, but 
this may represent stagnation and not innovation. A subset of 
cats suffering from FCGS remains refractory to the treatments 
evaluated in this systematic review, and to the authors’ knowledge 
there is no therapy that has adequately and convincingly been 
proven to achieve a 100% clinical remission rate. This most likely 
harkens back to the nebulous underlying etiology of FCGS and 
our current lack of understanding of its pathogenesis (12, 14). The 
authors of this systematic review agree that full-mouth or near 
full-mouth dental extractions is the current standard of care for 
FCGS (10, 41), but can we do better than the recently reported 
complete remission rate of 28.4% (41) that surgical management 
attains? The “holy grail” of FCGS research is to discover the etiol-
ogy of FCGS and to identify a treatment protocol that attains a 
near 100% remission rate. In order to progress toward this goal, 
a paradigm shift in FCGS research is necessary. New directions 
must be pursued, in which researchers focus on new and inno-
vative treatment strategies, such as modulating cats’ immune 
responses underlying their oral inflammation. As this type of 
research is already underway (10), future additional studies are 
required in order to ultimately discover both the cause and the 
cure for FCGS.
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